A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
ACADIA Pharmaceuticals Inc.
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Eligibility
- Age range
- 55–84 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female ≥55 years to \<85 years of age at the Screening visit living in the community or, if permitted by local regulations, in an institutionalized setting * Can provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met: 1. The subject's LAR must provide written informed consent. 2. The subject must provide written (if capable) informed assent per local regulations. * Meets either the clinical criteria for Parkinson's disease with dementia as defined by the Movemen…
Interventions
- DrugACP-204
Provided as 1 capsule, to be taken orally once daily
- DrugPlacebo
Provided as 1 capsule, to be taken orally once daily
Locations (54)
- ATP Clinical Research Inc.Irvine, California
- Georgetown UniversityWashington D.C., District of Columbia
- Humanity Clinical Research, CorpAventura, Florida
- Parkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, Florida
- K2 Medical Research Winter Garden LLCClermont, Florida
- University of Florida - ShandsGainesville, Florida